Given that the R&D productivity has declined over the years as far as small molecules are concerned, and the fact that there is a visible shift towards targeted therapies, Roche stands to gain
Roche's Competitive Advantage
#CompetitiveAdvantage, #Roche
Nessun commento:
Posta un commento